You have decided that one of your a 72-year-old patients should add a basal insulin dose to her antihyperglycemic regimen. During your discussion with her, she voices concern that between her “arthritic hands and poor vision” she won’t be able to accomplish this. You make the recommendation that using an insulin pen will make injection easier for her. Which of the following statement regarding insulin pens is true? Follow the link to take the quiz!

Early-on in DPP-4 Inhibitor drug development there was a product ready to go before Januvia. The pills were in the bottle, the booth was ready to go at ADA and then the drug was withdrawn from the market, because of reports of skin lesions. The word on the street indicated …

This week our Home Run Slides lay out a roadmap for insulin intensification, and the use of GLP-1 analogs and DPP4-I with insulin. If you follow the path your patients can safely intensify therapy with a greatly reduced risk of hypoglycemia. You can learn even more about all the different …

A 47 year-old patient has done an excellent job with lifestyle modifications and medication adherence, however she has not been able to yet achieve her individualized A1C goal. Her current regimen consists of a metformin, sitagliptin and insulin detemir (insulin started 4 months prior). However, over the past month as she has titrated her basal insulin towards her A1C goal, her self-glucose blood monitoring log shows large drops in her overnight glucose levels. After consulting with the treatment team, you decide to add rapid-acting prandial insulin to her regimen. How would you implement this strategy? Follow the link to take the quiz!

Treatment showed statistically significant improvements in pain relief and sleep quality.

Treatment found to reduce incidence of adenomas in patients with seemingly dose-dependent effect.

Closed-loop system at home over 12 weeks feasible in type 1 patients.

Probiotic does not change insulin sensitivity in glucose-tolerant individuals.

Oral insulin vaccine may protect beta-cells from autoimmune destruction.

Higher doses of medication may lead to a mean increase of approximately 1 cm height.